Regeneron (REGN) Tops Q3 EPS by 74c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Regeneron Pharma (REGN) PT Lowered to $880 at Leerink Partners
November 1, 2024 7:19 AM EDTLeerink Partners analyst Andrew Berens lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $880.00 (from $1,077.00) while maintaining a Market Perform rating.
The analyst comments "Bottom Line: We are reducing our REGN PT from $1,077 (22x old 2025E EPS of $48.96) to $880 (20x new 2025E EPS of $44.01). We... More
Regeneron Pharma (REGN) PT Lowered to $1,170 at Evercore ISI
October 31, 2024 4:35 PM EDTEvercore ISI analyst Cory Kasimov lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,170.00 (from $1,175.00) while maintaining a Outperform rating.
The analyst comments "Its been all tricks and no treats for REGN. Following todays 3Q print, shares are off another ~10%... More
